Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001)

Lung Cancer

Volumn 46, Issue 1, 2004, Pages 99-106

  Grossi, Francesco ^a   Belvedere, Ornella ^b   Fasola, Gianpiero ^b   Barbone, Fabio ^b   Rizzato, Simona ^b   Sibau, Angela ^b   Recchia, Leonardo ^c   Vigevani, Enrico ^d   Ceschia, Tino ^e   Morelli, Angelo ^e   Guglielmi, Alessandra ^a   Puglisi, Fabio ^b   Follador, Alessandro ^b   Talmassons, Giovanni ^e   Sobrero, Alberto F ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c San Polo Hospital   (Italy)

^d Tolmezzo Hospital   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Advanced; Chemotherapy; Non small cell lung cancer; Phase II; Sequential chemotherapy

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOACUSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; ONCOLOGY; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 4444345042     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.03.003     Document Type: Article

References (28)

1. The Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
2. Bunn P.A., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res. 5:1998;1087-1100
3. Kelly K., Crowley J., Bunn P.A., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19:2001;3210-3218
4. Schiller J.H., Harrington D., Belani C.P., et al. The Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:2002;92-98
5. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20:2002;4285-4291
6. Wozniak A.J., Crowley J.J., Balcerzak S., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a cooperative group study. J. Clin. Oncol. 10:1992;1066-1073
7. Sandler A., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced and metastatic non-small cell lung cancer. J. Clin. Oncol. 18:2000;122-130
8. Gatzemeier U., von Pawel J., Gottfried M., et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 18:2000;3390-3399
9. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 357:2001;1478-1484
10. Douillard J.Y., Eckardt J., Scagliotti G.V. Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer. 38:2002;S21-S28
11. Crino L., Scagliotti G.V., Ricci S., et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17:1999;3522-3530
12. Souquet P.J., Tan E.H., Rodrigues Pereira J., et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann. Oncol. 13:2002;1853-1861
13. Buccheri G.F., Ferrigno D., Curcio A., Vola F., Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer. 63:1989;428-432
14. Smith I.E., O'Brien M.E.R., Talbot D.C., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. 19:2001;1336-1343
15. Socinski M.A., Schell M.J., Peterman A., et al. Phase III comparing a defined duration of therapy versus continuos therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. 20:2002;1335-1343
16. Goldie J.H., Coldman A.J., Gudauskas G.A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat. Rep. 66:1982;439-449
17. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63:1979;1727-1733
18. Day R.S. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 46:1986;3876-3885
19. Norton L., Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep. 61:1977;1307-1317
20. Shepherd F.A. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin. Oncol. 26:1999;3-11
21. Giaccone G, Johnston DH, Manegold C, et al. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). In: Proceedings of the 27th ESMO Congress. Ann Oncol 2002;13(Suppl 5):131 (Abstract 4).
22. Johnston DH, Herbst R, Giaccone G. ZD1839 ("Iressa") in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). In: Proceedings of the 27th ESMO Congress. Ann Oncol 2002;13(Suppl 5):127 (Abstract 468).
23. Baselga J, Kris M, Yano S, et al. Phase II trials (IDEAL 1 and IDEAL 2) of ZD1839 in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients. In: Proceedings of the 27th ESMO Congress. Ann Oncol 2002;13(Suppl 5):131 (Abstract 481).
24. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials. 10:1989;1-10
25. Edelman M.J., Gandara D.R., Lau D.H.M., Lara P., Lauder I.J., Tracy D. Sequential combination chemotherapy in patients with advanced non-small cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel. Cancer. 92:2001;146-152
26. Clark J.I., Kancharla K., Qamar R., et al. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. Lung Cancer. 34:2001;271-277
27. Edelman MJ, Clark JI, Chansky K, John Crowley J, Albain K, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine (CARB/G) followed by paclitaxel (P) or cisplatin/vinorelbine (C/V) followed by docetaxel (D). Proc Am Soc Clin Oncol 2001;20:314a (Abstract 1254).
28. Feliu J., Martin G., Lizon J., et al. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. Ann. Oncol. 12:2001;1369-1374